Results 271 to 280 of about 205,631 (301)
Some of the next articles are maybe not open access.
Clinical Nuclear Medicine
Abstract A 62-year-old man was referred for a 68Ga–prostate-specific membrane antigen (PSMA) PET/CT scan for newly diagnosed prostate cancer (ISUP grade 5), on the background of left vestibular schwannoma treated with surgical excision 25 years ago.
Jeffrey, Chen +3 more
openaire +2 more sources
Abstract A 62-year-old man was referred for a 68Ga–prostate-specific membrane antigen (PSMA) PET/CT scan for newly diagnosed prostate cancer (ISUP grade 5), on the background of left vestibular schwannoma treated with surgical excision 25 years ago.
Jeffrey, Chen +3 more
openaire +2 more sources
Prostate‐specific membrane antigen
British Journal of Urology, 1998B H, Maraj, P, Whelan, A F, Markham
openaire +2 more sources
Clinical Nuclear Medicine
A 74-year-old man with metastatic castration-resistant prostate cancer underwent 2 cycles of [177Lu]Lu-prostate-specific membrane antigen (PSMA) therapy. Despite declining prostate-specific antigen (PSA) levels and pain relief throughout the first 4 months of [177Lu]Lu-PSMA therapy, follow-up [68Ga]Ga-PSMA PET/CT revealed progressive skeletal ...
Ahmed Saad Abdlkadir +3 more
openaire +1 more source
A 74-year-old man with metastatic castration-resistant prostate cancer underwent 2 cycles of [177Lu]Lu-prostate-specific membrane antigen (PSMA) therapy. Despite declining prostate-specific antigen (PSA) levels and pain relief throughout the first 4 months of [177Lu]Lu-PSMA therapy, follow-up [68Ga]Ga-PSMA PET/CT revealed progressive skeletal ...
Ahmed Saad Abdlkadir +3 more
openaire +1 more source
Prostate‐specific membrane antigen expressing angiolipoma
ANZ Journal of Surgery, 2020Xuan Rui Sean Ong +3 more
openaire +2 more sources
Integrative oncology: Addressing the global challenges of cancer prevention and treatment
Ca-A Cancer Journal for Clinicians, 2022Jun J Mao,, Msce +2 more
exaly
Overview of prostate-specific membrane antigen.
Reviews in urology, 2011Efforts to evaluate and discover diagnostic and therapeutic markers for prostate cancer continue. One of these, prostate-specific membrane antigen (PSMA), a transmembrane protein expressed in all types of prostatic tissue, remains a useful diagnostic and possibly therapeutic target.
openaire +1 more source
Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
Ca-A Cancer Journal for Clinicians, 2020Aaron J Grossberg +2 more
exaly
Oral complications of cancer and cancer therapy
Ca-A Cancer Journal for Clinicians, 2012Joel B Epstein +2 more
exaly

